Cargando…
Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study
BACKGROUND: Although hypertension is the most common risk factor for atrial fibrillation (AF), whether blood pressure (BP) control varies across the spectrum of stroke risk in patients with AF or by adequacy of their thromboprophylaxis management is unclear. METHODS: We examined data from the RE-LY...
Autores principales: | McAlister, Finlay A., Mian, Rajibul, Oldgren, Jonas, Wallentin, Lars, Ezekowitz, Michael, Yusuf, Salim, Connolly, Stuart J., Healey, Jeff S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961825/ https://www.ncbi.nlm.nih.gov/pubmed/31940361 http://dx.doi.org/10.1371/journal.pone.0226259 |
Ejemplares similares
-
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial
por: Hijazi, Ziad, et al.
Publicado: (2019) -
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2020) -
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
por: Verdecchia, Paolo, et al.
Publicado: (2018) -
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
por: Pol, Tymon, et al.
Publicado: (2021) -
Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials
por: Hijazi, Ziad, et al.
Publicado: (2020)